Breaking With Tradition
Before adopting continuous manufacturing practices, companies need to assess the potential pros and cons for their operations
Mark Muldowney | | Longer Read
Continuous manufacturing is the norm in many industries, but for pharma – despite the well-documented cost and quality benefits associated with continuous – batch manufacturing remains king. The availability of standard batch reactors and the simplicity of their use means that old habits die hard.
With many continuous processes relatively untested and with regulatory guidance somewhat lacking, the industry’s hesitance to embrace continuous is understandable. For continuous manufacturing to be more widely adopted, companies must be aware of its operational advantages as well as the challenges posed by its use. Armed with this knowledge, companies can fully assess whether continuous processes are appropriate for their business needs.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine